| 9/15/2016 | CVIG | S&P: Gilead Sciences notes A
|
| 9/15/2016 | CVIG | Moody’s gives A3 to Gilead notes
|
| 5/18/2016 | CVIG | Moody’s cuts Gilead Sciences to stable
|
| 4/5/2016 | CV | Market Commentary: Convertibles steady despite slip in stocks; Gilead active ahead of maturity; Tesla firmer
|
| 4/5/2016 | CV | Market Commentary: Morning Commentary: Convertibles steady despite slip in stocks; Gilead active ahead of maturity
|
| 3/4/2016 | CV | Gilead Sciences will settle 1.625% convertible notes due 2016 in cash
|
| 10/2/2015 | CV | Market Commentary: Convertibles decline on weak jobs report, pare losses by the bell; liquidity constrained
|
| 9/9/2015 | CVIG | S&P rates Gilead notes A-
|
| 9/9/2015 | CVIG | Moody’s rates Gilead notes A3
|
| 2/4/2015 | CV | Market Commentary: Microchip plans $1 billion new deal; Gilead Sciences in focus; Brocade lifts with shares
|
| 2/4/2015 | CV | Market Commentary: Morning Commentary: Gilead Sciences in focus after earnings; Brocade convertibles up with shares
|
| 12/24/2014 | CV | Market Commentary: American Realty bonds add a point with shares lower; market quiet ahead of holiday
|
| 12/23/2014 | CV | Market Commentary: Trading tapers before holiday; Gilead Sciences steady on hedge; Royal Gold better to buy
|
| 12/22/2014 | CV | Market Commentary: Gilead drops in line with shares on Express Scripts news; MGM weaker; recent deals trade
|
| 12/22/2014 | CV | Market Commentary: Morning Commentary: Gilead lower outright after Express Scripts-AbbVie deal; MGM weaker again
|
| 11/12/2014 | CVIG | S&P: Gilead Sciences notes A-
|
| 11/12/2014 | CVIG | Moody’s provides A3 to Gilead notes
|
| 11/11/2014 | CVIG | Moody’s upgrades Gilead
|
| 9/18/2014 | CV | Market Commentary: PDL BioPharma drops after auditor news; Gilead remains weaker; secondary softness persists
|
| 9/2/2014 | CV | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
| 8/18/2014 | CV | Market Commentary: Gilead Sciences active, trading below parity; Priceline off a bit; USEC convertibles flat
|
| 8/18/2014 | CV | Market Commentary: Morning Commentary: Priceline off a bit in early trade; Gilead active, less 1.5 points to parity
|
| 4/22/2014 | CV | Market Commentary: Earnings drive convertibles action; Medidata tanks outright, adds on hedge; Rambus in line
|
| 4/9/2014 | CV | Market Commentary: WellPoint flat to higher in active trade; larger, higher-grade issues trade; RPM in focus
|
| 3/28/2014 | CV | Gilead opts to settle conversions of 1% senior notes due 2014 in cash
|
| 3/21/2014 | CV | Market Commentary: Convertibles quiet; National Health lags dollar neutral; Navistar 'holds in;' Sterlite gains
|
| 3/4/2014 | CVIG | Moody's rates Gilead's notes Baa1
|
| 3/4/2014 | CVIG | S&P assigns Gilead debt A-
|
| 2/11/2014 | CV | Market Commentary: Planned AMAG looks cheap; Canadian Solar launches; WebMD slips outright, adds on hedge
|
| 12/9/2013 | CVIG | Moody's: Gilead view to positive
|
| 10/21/2013 | CV | Market Commentary: Convertibles 'tread water' ahead of data, earnings reports; planned Crown Castle deal eyed
|
| 7/26/2013 | CV | Market Commentary: Level 3 strong after earnings; Tesla extends gains; Goodrich better; American Realty weak
|
| 7/8/2013 | CV | Market Commentary: Convertibles firmer; shorter-dated issues holding up; Peabody, longer-dated names weaker
|
| 6/21/2013 | CV | Market Commentary: Convertibles heavier as fear dominates tone; bank preferreds down; IG paper lower in line
|
| 4/22/2013 | CV | Market Commentary: Integra LifeSciences flat to lower; Vertex quiet after surge; Intel, Microsoft in trade
|
| 2/4/2013 | CV | Market Commentary: Gilead Sciences steady ahead of earnings; Medtronic active; SandRidge lower on trust news
|
| 1/15/2013 | CV | Market Commentary: Amgen sees sellers ahead of maturity; Gilead Ds better; Lennar slips; Pacira to price
|
| 1/14/2013 | CV | Market Commentary: Dendreon adds outright; InterMune intends to price notes, shares; Lennar earnings on tap
|
| 12/24/2012 | CV | Market Commentary: Convertibles quiet in shortened, pre-holiday session; Greatbatch trades higher on call
|
| 12/3/2012 | CV | Market Commentary: Teva trades after disappointing outlook; Volcano's planned $350 million convertible on tap
|
| 11/30/2012 | CV | Market Commentary: VeriSign drops outright in active trade but improves on hedge; larger, liquid names active
|
| 11/27/2012 | CV | Market Commentary: Convertibles thinly traded; NetApp steady after Monday's slip; DryShips extends gains
|
| 11/26/2012 | CV | Market Commentary: DryShips jumps as rebound continues; Knight Capital slightly higher; Trina Solar in focus
|
| 11/16/2012 | CV | Market Commentary: DryShips, CEDC extend drops; new paper mixed, AK Steel falls to 96; Vector pushes over 104
|
| 11/13/2012 | CV | Market Commentary: Gilead trades mixed on data; Vertex in line; CEDC sinks in light trade; GT Advanced down
|
| 11/9/2012 | CV | Market Commentary: James River, Alpha Natural little moved as shares fall; SandRidge flat to slightly higher
|
| 10/24/2012 | CV | Market Commentary: NuVasive trades flattish as shares jump; Navistar gains as shares slip; EMC paper active
|
| 10/23/2012 | CV | Market Commentary: RadioShack strengthens with buyback news; Gilead 'up small' ahead of earnings; AMD lower
|
| 10/17/2012 | CV | Market Commentary: Intel flat to lower outright, up on hedge; Knight firm; Stillwater, WellPoint doing well
|
| 10/9/2012 | CV | Market Commentary: Convertibles quiet; Cemex slips with stock; James River 4.5% adds; Penn Virginia to price
|
| 10/3/2012 | CV | Market Commentary: New WellPoint up on debut; Ares Capital on tap; existing Ares paper quiet; NuVasive drops
|
| 10/2/2012 | CV | Market Commentary: WellPoint adds in the gray, models attractively; Molina, Amerigroup quiet; Illumina eyed
|
| 9/25/2012 | CV | Market Commentary: GT Advanced Technologies lifts despite lower shares; Navistar drops; Amgen, Gilead active
|
| 9/19/2012 | CV | Market Commentary: New Ctrip.com jumps on debut; Chiquita paper improves; Gilead on a tear; TICC, XPO on tap
|
| 9/18/2012 | CV | Market Commentary: Suntech adds on production cut; SunPower higher; Alpha Natural up; Hovnanian, Ctrip on tap
|
| 9/17/2012 | CV | Market Commentary: General Cable up on potential tender; Gilead jumps on HIV drug; AMR holds on to gains
|
| 9/5/2012 | CV | Market Commentary: Toll Brothers trades unchanged on debut; Medicis in another 0.125 point; IG names active
|
| 8/31/2012 | CV | Market Commentary: Convertibles mostly flat for week; some see mixed performance for month, but indices gain
|
| 8/24/2012 | CV | Market Commentary: Convertibles mostly quiet; Gilead comes in slightly; Vertex static; Endo moves up a little
|
| 8/21/2012 | CV | Market Commentary: MolyCorp trades weakly on second day in the market; Medtronic active ahead of earnings
|
| 8/20/2012 | CV | Market Commentary: MolyCorp trades weakly on second day in the market; Medtronic active ahead of earnings
|
| 8/2/2012 | CV | Market Commentary: Knight swings wildly, extends slide after 'glitch'; Gilead adds on rival's suspended trial
|
| 7/30/2012 | CV | Market Commentary: Convertibles mostly quiet; Kodak gains ahead of auction; Navistar firms; SanDisk mixed
|
| 7/27/2012 | CV | Market Commentary: Amgen in line to slightly lower on earnings; Gilead, Coinstar in line as well; Amarin off
|
| 7/24/2012 | CV | Market Commentary: WebMD down on warning; Dendreon better on takeout rumor; Virgin Media tighter after earnings
|
| 7/19/2012 | CV | Market Commentary: Amgen keeps tracking higher with shares; Xilinx gains on hedge; Kodak retakes 20; AMR up
|
| 6/27/2012 | CV | Market Commentary: High-grade names in focus; Lennar adds; Isis under pressure; Gevo to price $30 million
|
| 6/5/2012 | CV | Market Commentary: Central European drops on restatement news; Illumina comes in slightly; Medicines Co. on tap
|
| 4/27/2012 | CV | Market Commentary: Amgen adds 0.25 point on hedge; Micron C notes weaker, but catches bid; Chesapeake pressured
|
| 4/19/2012 | CV | Market Commentary: Human Genome adds outright, slides on hedge; New Titan gains dollar neutral; Gilead mixed
|
| 4/13/2012 | CV | Market Commentary: New Microns slip below par in secondary market; Coinstar up on strong preliminary results
|
| 4/5/2012 | CV | Market Commentary: Convertibles soften ahead of holiday weekend; L-3 steady with lower shares; CETV comes in
|
| 4/4/2012 | CV | Market Commentary: SanDisk 1.5% convertibles come in on hedge; NetApp trades in line; Western Refining adds
|
| 4/2/2012 | CV | Market Commentary: Convertibles flat to weaker: Gilead weaker, unchanged on hedge; James River down on hedge
|
| 3/23/2012 | CV | Market Commentary: New Cenveo climbs on debut; Vornado steady, active in trade; investment-grade names mixed
|
| 3/13/2012 | CV | Market Commentary: New Salix pops, then retreats on debut; Medivation talk revised; Wintrust notes to price
|
| 2/22/2012 | CV | Market Commentary: Central European Media slips after disappointing earnings; MGIC adds; NuVasive in focus
|
| 2/21/2012 | CV | Market Commentary: Gilead lower outright, mixed on hedge; SunPower, Suntech Power edge up; RadioShack adds
|
| 2/17/2012 | CV | Market Commentary: Gilead jumps after negative drug study; SunPower gains on earnings beat; Suntech higher
|
| 2/17/2012 | CVIG | Moody's says Gilead announcement is negative
|
| 2/14/2012 | CV | Market Commentary: Convertibles weaken some; Gilead mixed; Charles River flat on earnings; DryShips jumps
|
| 2/10/2012 | CV | Market Commentary: Alcatel-Lucent up on strong earnings; Gilead, Amgen mixed on hedged basis; Siemens prices
|
| 2/8/2012 | CV | Market Commentary: Gilead edges up further on swap; RadioShack steady; Hutchinson jumps; solar names in focus
|
| 2/6/2012 | CV | Market Commentary: Convertibles firm; Gilead slips on hedge; DryShips gains outright, little changed on hedge
|
| 2/3/2012 | CV | Market Commentary: Gilead adds on hedge on positive drug data; Tyson contracts on hedge; MannKind drops deal
|
| 1/18/2012 | CV | Market Commentary: Amgen, Gilead improve on hedge; D.R. Horton, Synnex trade mostly in line; Cheniere slips
|
| 12/20/2011 | CV | Market Commentary: Jefferies recoups, moves higher with positive earnings; Navistar looks better on earnings
|
| 12/19/2011 | CV | Market Commentary: Amgen edges higher; Gilead mixed to higher; Jefferies lower; MF Global adds a few points
|
| 12/16/2011 | CV | Market Commentary: Gilead lower after trial setback; new AmTrust slips; FiberTower doesn't cure default
|
| 12/6/2011 | CVIG | S&P assigns Gilead notes A-
|
| 12/6/2011 | CVIG | Moody's: Gilead notes Baa1
|
| 12/6/2011 | CV | Market Commentary: Dendreon adds on sale of royalty interest; Gilead trades on debt offering; Clearwire jumps
|
| 11/29/2011 | CV | Market Commentary: AMR collapses after bankruptcy filing; Transocean Cs improve; Onyx seen lower on hedge
|
| 11/22/2011 | CV | Market Commentary: Lennar launches new deal; Existing Lennar slips; Frontline tumbles; Gilead bounces some
|
| 11/21/2011 | CVIG | S&P affirms Gilead Sciences
|
| 11/21/2011 | CVIG | Moody's affirms Gilead
|
| 11/21/2011 | CV | Market Commentary: Gilead lower outright, mixed on hedge; Transocean, MF Global lower; 3D Systems prices
|
| 10/24/2011 | CV | Market Commentary: Convertibles rise on light volume; Radian up; hedged players lose on RightNow's Oracle offer
|
| 9/12/2011 | CV | Market Commentary: Global Industries surges on takeover offer; Hornbeck up 2-3 points; Clearwire weakens
|
| 8/17/2011 | CV | Market Commentary: Kodak soars on patent sale speculation; AMD, Intel slip; EMC, Gilead follow market lower
|
| 6/13/2011 | CV | Market Commentary: Convertibles mostly weaker; solar names stabilize, but SunPower lags; BroadSoft to price
|
| 6/13/2011 | CVIG | Moody's: Gilead unchanged
|
| 5/3/2011 | CV | Market Commentary: Mylan off outright, expands on hedge; Incyte premium comes in; Alaska Communications on tap
|
| 4/25/2011 | CV | Market Commentary: Central European Distribution gains outright; RadioShack up after earnings; Apollo on tap
|
| 4/21/2011 | CV | Market Commentary: Gilead, United Continental slip; Dendreon, WebMD, GM islands of activity in quiet session
|
| 4/19/2011 | CV | Market Commentary: Gilead, Virgin eyed ahead of earnings; Molina adds on positive results; Clearwire gains
|
| 4/18/2011 | CV | Market Commentary: Convertibles weaken some; Amylin flat; Gilead mostly lower; A123 Systems sheds a point
|
| 3/24/2011 | CV | Market Commentary: James River upsizes, jumps on debut; Ares, Gilead add to gains; Best Buy slips with earnings
|
| 3/23/2011 | CV | Market Commentary: Ares, Photronics jump on debuts; Gilead gains on deal; James River up in gray; Kinross up
|
| 3/23/2011 | CVIG | S&P rates Gilead notes A-
|
| 3/23/2011 | CVIG | Moody's rates Gilead notes Baa1
|
| 3/23/2011 | CVIGPF | Gilead Sciences files automatic shelf for stock, preferreds and debt
|
| 3/9/2011 | CV | Market Commentary: New WebMD reoffered at 98.75; new TiVo higher but quiet; upsized Cemex, ReneSola on tap
|
| 1/25/2011 | CV | Citi says replace $15 billion of maturing converts with AngloGold, Boston Properties, among others
|
| 10/20/2010 | CV | Market Commentary: New Cubist trades slightly over par; Amylin gets slammed but pares losses; Gilead quiet
|
| 8/11/2010 | CV | Gilead greenshoe fully exercised, lifting convertibles to $2.5 billion
|
| 7/30/2010 | CV | Market Commentary: A&P bonds recoup some losses; Gilead flat; Virgin Media slips; issuance tracks 2009 pace
|
| 7/28/2010 | CV | Market Commentary: Convertibles crimped by batch of poor earnings; Hutchinson, Kodak, International Game down
|
| 7/27/2010 | CV | New Issue: Gilead Sciences sells $2.2 billion four-, six-year convertible notes
|
| 7/27/2010 | CV | Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
|
| 7/26/2010 | CV | New Issue: Gilead Sciences sells $2.2 billion four-, six-year convertible notes
|
| 7/26/2010 | CV | Market Commentary: Gilead active, weaker on new notes; AMD mostly quiet, higher on tender; Alcoa trades in line
|
| 7/21/2010 | CV | Market Commentary: Apache up a little in the gray; Genco quiet ahead of pricing; United Rentals, Cephalon add
|
| 7/20/2010 | CV | Market Commentary: Apache plans $1.1 billion sale of convertible mandatories; MGIC 'comes in' dollar neutral
|
| 7/19/2010 | CV | Market Commentary: AMR, UAL lower on disappointing Delta earnings; Transocean slips; Newmont Mining steady
|
| 6/9/2010 | CV | Market Commentary: Microsoft slips below par on debut; Transocean weaker; National Financial, Cadence on tap
|
| 4/28/2010 | CV | Market Commentary: Convertibles mixed to weaker; PMI, MGIC lower; Newmont Mining up; Synovus at 101 in gray
|
| 4/23/2010 | CV | Market Commentary: Health care names recover; investment-grade names in focus; Incyte, Textron strengthen
|
| 4/21/2010 | CV | Market Commentary: MGIC soars on debut; Evergreen Solar active on new issue, tender; Gilead Sciences improves
|
| 1/26/2010 | CV | Market Commentary: Convertibles under pressure; EMC recoups; Amylin strengthens; Kinetic Concepts paper in trade
|
| 1/25/2010 | CV | Market Commentary: EMC extends losses ahead of earnings; Amgen, Boston Properties little changed; UAL drops
|
| 10/16/2009 | CV | Market Commentary: Sterlite adds on debut; AMR, Gilead slip lower with shares; AMD stronger after earnings
|
| 5/12/2009 | CV | Gilead Palo Alto tenders for any and all of $292.22 million 2.75%, 3.25%, 2% convertibles
|
| 4/27/2009 | CV | Market Commentary: GM rises on exchange; Gilead edges up on swine flu; SunPower, United States Steel to price
|
| 3/12/2009 | CV | Gilead to assume $292 million in CV Therapeutics' convertible debt
|
| 3/12/2009 | CV | Market Commentary: CV Therapeutics higher, Gilead slips on merger news; Johnson Controls convertibles move upward
|
| 1/21/2009 | CV | Market Commentary: Financial preferreds bounce a little from big drop; health care, biotech names in trade; Avnet edges higher
|
| 9/2/2008 | CV | Market Commentary: Chesapeake Energy mixed to slightly better as oil falls; Gilead eases; Sciele gains on buyout bid
|
| 10/19/2007 | CV | Market Commentary: Gilead falls after positive earnings; Medtronic drags down St. Jude; AMD weighs down Intel; Yahoo! gives back
|
| 3/1/2007 | CV | Market Commentary: Amgen slips on inquiry, drug concerns; Gilead firms on trial results; Hospitality Properties absent in gray
|
| 12/1/2006 | CV | Market Commentary: JDS Uniphase firm on sector concerns; Goodrich quiet in debut; Amgen, Gilead hit on broad pullback
|
| 10/2/2006 | CV | Market Commentary: Harrah's offer cuts into hedges; Gilead slips outright on Myogen acquisition; World Acceptance plans deal
|
| 8/29/2006 | BTCV | New Issue: HSBC USA prices $0.765 million 18% reverse convertibles linked to Gilead Sciences
|
| 8/2/2006 | CV | HSBC USA plans issue of reverse convertibles linked to Gilead Sciences
|
| 7/20/2006 | BTCV | Gilead reports second quarter net income of $265.2 million; revenues driven by HIV franchise
|
| 7/10/2006 | CV | Market Commentary: SanDisk gains on speculation; Gilead improves ahead of results; Archstone-Smith plans overnight deal
|
| 6/27/2006 | CV | Market Commentary: MedImmune, Gilead trade; Vector launches overnight deal; Chesapeake prices
|
| 6/20/2006 | CV | Market Commentary: Medtronic, Amgen fall prey to selling pressure; JetBlue adds; Actuant plunges
|
| 6/9/2006 | CV | Market Commentary: Advanced Medical brushes off Fitch downgrade; Gilead, Amgen, Trinity gain; L-3 unchanged
|
| 5/26/2006 | CV | Market Commentary: Credence firm despite downgrades; Cubist gains on FDA approval; Nabors, Transocean up with stocks
|
| 5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
| 5/2/2006 | CV | Market Commentary: Apex Silver falls on Bolivia concerns; Quicksilver gains on earnings anticipation; Sirius up on guidance
|
| 5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
| 4/26/2006 | CV | Market Commentary: General Motors' gains boost auto sector; Flextronics up on rival's earnings; Quanta plans $125 million deal
|
| 4/25/2006 | BTCV | Gilead greenshoe exercised, raising two convertibles to $650 million each
|
| 4/24/2006 | CV | Market Commentary: Bausch and Lomb, Schlumberger get analysts' thumbs up; Halliburton, Medtronic shrug off reports
|
| 4/21/2006 | CV | Market Commentary: Mercury Interactive gains on waiver consent offer; Vitesse marked lower on delayed filings
|
| 4/20/2006 | CV | Market Commentary: General Motors gains, Intel falls on quarterly results; Gilead new deal stumbles on debut;
|
| 4/19/2006 | CV | Market Commentary: ExpressJet stands firm on lost business; Gilead deal priced cheaper than talk; Cephalon gains on new data
|
| 4/19/2006 | BTCV | New Issue: Gilead prices $1.2 billion of convertibles; 5-years at 0.5%, up 19%, 7-years at 0.625%, up 17%
|
| 4/18/2006 | BTCV | Gilead talks $1.1 billion convertibles; 5 years at 0-0.5%, up 20-25%; 7 years at 0.125-0.625%, up 19-24%
|
| 4/18/2006 | CV | Market Commentary: Freeport-McMoran surges on strong earnings; JDS Uniphase rebounds; Gilead plans $1.1 billion deal
|
| 4/18/2006 | BTCV | New Issue: Eksportfinans prices $2.453 million 10% notes linked to Gilead Sciences
|
| 12/23/2005 | BTCV | New Issue: Morgan Stanley prices $23 million 7.5% Sparqs exchangeable for Gilead Sciences
|
| 11/22/2004 | CV | Gilead Sciences says holders converted all $345 million notes ahead of redemption
|
| 10/6/2004 | CV | Gilead calls all $345 million of 2% convertibles
|
| 9/30/2004 | CV | Market Commentary: Ford, GM convertibles see little traffic ahead of Sept sales; Schering-Plough shoots up
|
| 1/30/2004 | CV | Market Commentary: GATX mixed on dividend cut; Nortel results impress players; Gilead weaker on drug worries
|
| 12/22/2003 | CV | Gilead says all 5% convertibles exchanged for stock ahead of call
|
| 11/20/2003 | CV | Gilead Sciences to redeem 5% convertibles
|
| 10/29/2003 | CV | Market Commentary: Gilead plunges 11-30 points on earnings disappointment; Northwest, Elan deals pops up;
|
| 10/13/2003 | CV | Market Commentary: Beverly Enterprises launches $100 million deal for Wednesday; Ptek pays off on Texas hedge
|
| 10/2/2003 | CV | Market Commentary: Providian gains sharply amidst big volume on talk about Wells Fargo takeover; buyers aplenty
|
| 8/28/2003 | CV | Market Commentary: Miscellaneous scraps of convertible paper trading; action to heat up next week
|
| 8/5/2003 | CV | Market Commentary: Further cheapening noted, but many buyers waiting in wings; new deal slate remains active
|
| 3/12/2003 | CV | Merrill adds Gilead 2% convertible to model portfolio on attractive risk/reward profile
|
| 12/16/2002 | CV | Market Commentary: Market watches stocks gain from sidelines, Phoenix in market with small deal
|
| 12/13/2002 | CV | New Issue: Gilead Sciences $300 million convertibles yield 2.0%, up 25.74%
|
| 12/13/2002 | CV | Market Commentary: Market treads water while stocks, credit spreads flounder
|
| 12/12/2002 | CV | Gilead Sciences overnight $300 million convertible talked at 2.0-2.5% yield, up 20-25%
|
| 12/12/2002 | CV | Market Commentary: Ciena boosts telecom names; market trades sideways amid spate of last-minute new deals
|
| 9/18/2002 | CV | Market Commentary: JPMorgan tugs on financials, transports fall on war worries
|
| 8/6/2002 | CV | Market Commentary: Prices, trading volumes gain on short covering, stock bounce
|
| 7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
| 5/15/2002 | CV | Market Commentary: Pep Boys advances pricing; market run ends in thud
|
| 1/4/2002 | CV | Market Commentary: Convertibles higher as prospects of new deals spur activity
|
